Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
Phase 1
Not yet recruiting
- Conditions
- AML - Acute Myeloid Leukemia
- Interventions
- Drug: Dexamethasone plus Venetoclax-based Low-Intensity Therapy
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 20
- Registration Number
- NCT07014462
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 32
- Registration Number
- NCT07008638
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT07007312
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Phase 3
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Elderly
- Interventions
- Drug: Intermediate-dose Cytarabine in Combination with Venetoclax
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Yehui Tan
- Target Recruit Count
- 68
- Registration Number
- NCT06990321
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Debio 1562M
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 134
- Registration Number
- NCT06969430
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸The Ohio Sate University, Columbus, Ohio, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Phase 1
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Chronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Refractory Chronic Myelomonocytic LeukemiaCMMLAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemias
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Solu Therapeutics, Inc
- Target Recruit Count
- 105
- Registration Number
- NCT06950034
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
Not Applicable
Recruiting
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia (AML)Acute Lymphocytic Leukaemia
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Donald Arnold
- Target Recruit Count
- 60
- Registration Number
- NCT06947044
- Locations
- 🇨🇦
Juravinski Hospital, Hamilton, Ontario, Canada
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)
Phase 2
Not yet recruiting
- Conditions
- Core Binding Factor Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 162
- Registration Number
- NCT06917911
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Early Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Biological: TCR-T Cells Injection
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06904859
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
Recruiting
- Conditions
- AML, Adult
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 1000
- Registration Number
- NCT06891144
- Locations
- 🇫🇷
Angers CHU, Angers, France
🇫🇷Annecy CH, Annecy, France
🇫🇷Avignon CH, Avignon, France